Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis.
Schiele MA, Reif A, Lin J, Alpers GW, Andersson E, Andersson G, Arolt V, Bergström J, Carlbring P, Eley TC, Esquivel G, Furmark T, Gerlach AL, Hamm A, Helbig-Lang S, Hudson JL, Lang T, Lester KJ, Lindefors N, Lonsdorf TB, Pauli P, Richter J, Rief W, Roberts S, Rück C, Schruers KRJ, Thiel C, Wittchen HU, Domschke K, Weber H, Lueken U. Schiele MA, et al. Among authors: helbig lang s. Eur Neuropsychopharmacol. 2021 Mar;44:105-120. doi: 10.1016/j.euroneuro.2021.01.004. Epub 2021 Jan 20. Eur Neuropsychopharmacol. 2021. PMID: 33483252
Association of rs7688285 allelic variation coding for GLRB with fear reactivity and exposure-based therapy in patients with panic disorder and agoraphobia.
Ridderbusch IC, Richter J, Yang Y, Hoefler M, Weber H, Reif A, Hamm A, Pané-Farré CA, Gerlach AL, Stroehle A, Pfleiderer B, Arolt V, Wittchen HU, Gloster A, Lang T, Helbig-Lang S, Fehm L, Pauli P, Kircher T, Lueken U, Straube B. Ridderbusch IC, et al. Among authors: helbig lang s. Eur Neuropsychopharmacol. 2019 Oct;29(10):1138-1151. doi: 10.1016/j.euroneuro.2019.07.133. Epub 2019 Aug 20. Eur Neuropsychopharmacol. 2019. PMID: 31444036 Clinical Trial.
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes.
Gottschalk MG, Richter J, Ziegler C, Schiele MA, Mann J, Geiger MJ, Schartner C, Homola GA, Alpers GW, Büchel C, Fehm L, Fydrich T, Gerlach AL, Gloster AT, Helbig-Lang S, Kalisch R, Kircher T, Lang T, Lonsdorf TB, Pané-Farré CA, Ströhle A, Weber H, Zwanzger P, Arolt V, Romanos M, Wittchen HU, Hamm A, Pauli P, Reif A, Deckert J, Neufang S, Höfler M, Domschke K. Gottschalk MG, et al. Among authors: helbig lang s. Transl Psychiatry. 2019 Feb 4;9(1):75. doi: 10.1038/s41398-019-0415-8. Transl Psychiatry. 2019. PMID: 30718541 Free PMC article.
Transfer of exposure therapy effects to a threat context not considered during treatment in patients with panic disorder and agoraphobia: Implications for potential mechanisms of change.
Richter J, Pané-Farré CA, Gerlach AL, Gloster AT, Wittchen HU, Lang T, Alpers GW, Helbig-Lang S, Deckert J, Fydrich T, Fehm L, Ströhle A, Kircher T, Arolt V, Hamm AO. Richter J, et al. Among authors: helbig lang s. Behav Res Ther. 2021 Jul;142:103886. doi: 10.1016/j.brat.2021.103886. Epub 2021 May 12. Behav Res Ther. 2021. PMID: 34023593
Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT.
Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T, Fehm L, Hamm AO, Richter J, Alpers GW, Gerlach AL, Ströhle A, Kircher T, Deckert J, Zwanzger P, Höfler M, Arolt V. Gloster AT, et al. J Consult Clin Psychol. 2011 Jun;79(3):406-20. doi: 10.1037/a0023584. J Consult Clin Psychol. 2011. PMID: 21534651 Clinical Trial.
Mechanism of action in CBT (MAC): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoraphobia.
Gloster AT, Wittchen HU, Einsle F, Höfler M, Lang T, Helbig-Lang S, Fydrich T, Fehm L, Hamm AO, Richter J, Alpers GW, Gerlach AL, Ströhle A, Kircher T, Deckert J, Zwanzger P, Arolt V. Gloster AT, et al. Eur Arch Psychiatry Clin Neurosci. 2009 Nov;259 Suppl 2:S155-66. doi: 10.1007/s00406-009-0065-6. Eur Arch Psychiatry Clin Neurosci. 2009. PMID: 19876674 Clinical Trial.
MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy.
Ziegler C, Richter J, Mahr M, Gajewska A, Schiele MA, Gehrmann A, Schmidt B, Lesch KP, Lang T, Helbig-Lang S, Pauli P, Kircher T, Reif A, Rief W, Vossbeck-Elsebusch AN, Arolt V, Wittchen HU, Hamm AO, Deckert J, Domschke K. Ziegler C, et al. Transl Psychiatry. 2016 Apr 5;6(4):e773. doi: 10.1038/tp.2016.41. Transl Psychiatry. 2016. PMID: 27045843 Free PMC article.
A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety.
Hommers LG, Richter J, Yang Y, Raab A, Baumann C, Lang K, Schiele MA, Weber H, Wittmann A, Wolf C, Alpers GW, Arolt V, Domschke K, Fehm L, Fydrich T, Gerlach A, Gloster AT, Hamm AO, Helbig-Lang S, Kircher T, Lang T, Pané-Farré CA, Pauli P, Pfleiderer B, Reif A, Romanos M, Straube B, Ströhle A, Wittchen HU, Frantz S, Ertl G, Lohse MJ, Lueken U, Deckert J. Hommers LG, et al. Among authors: helbig lang s. Transl Psychiatry. 2018 Oct 19;8(1):226. doi: 10.1038/s41398-018-0278-4. Transl Psychiatry. 2018. PMID: 30341278 Free PMC article.
23 results